Understanding Your Prescription Weight Loss Treatment Options
Can You Change From Wegovy To Mounjaro: Key Treatment Differences
When considering whether you can change from Wegovy to Mounjaro, it's essential to understand the fundamental differences between these prescription weight loss treatments. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural fullness hormones to reduce appetite and promote satiety. Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist that targets two hormone pathways simultaneously. Both are prescription-only medicines requiring clinical assessment and ongoing medical supervision.
The decision to change from Wegovy to Mounjaro should always be made in consultation with a qualified prescriber who can assess your individual response, tolerability, and weight management goals. At EverydayMeds, our clinical team evaluates each patient's circumstances when considering treatment transitions. Factors such as side effect profile, dosing convenience, and treatment response all play crucial roles in determining the most suitable option for your prescription weight loss journey.
Wegovy Pricing and Treatment Value for Weight Management
Understanding the cost implications when you change from Wegovy to Mounjaro requires examining the pricing structure of each treatment. Wegovy follows a structured dose escalation schedule starting at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to the maintenance dose of £209.99 (2.4mg). Our discount codes FIRST40 for new customers and DOSE25 for returning customers are applied at checkout to reach these final prices. Bundle options like our Intro Trio (0.25mg, 0.5mg, and 1mg) at £299.99 provide three months of initial treatment with Reliable Supply continuity.
The investment in prescription weight loss treatment extends beyond the medication cost to encompass the comprehensive clinical support provided. Each Wegovy prescription includes prescriber assessment, ongoing monitoring, and access to our clinical team for treatment guidance. When considering whether you can change from Wegovy to Mounjaro, factor in the different dosing schedules, storage requirements, and clinical monitoring needs. Both treatments represent significant commitments to long-term weight management alongside lifestyle modifications.
Clinical Evidence Supporting Treatment Changes From Wegovy
The decision of whether you can change from Wegovy to Mounjaro should be informed by clinical evidence from major trials. In the STEP programme, patients taking Wegovy alongside diet and exercise achieved average weight losses of approximately 15% at 68 weeks in STEP 1, with sustained results of 15.2% at two years in STEP 5 (Wilding et al., NEJM, 2021). These results demonstrate Wegovy's efficacy as a prescription weight loss intervention when combined with lifestyle modifications.
Mounjaro's clinical evidence comes from the SURMOUNT trials, showing its own efficacy profile in weight management. However, direct head-to-head comparisons between the treatments are limited due to different trial designs and populations. When you change from Wegovy to Mounjaro, your prescriber will consider your individual response pattern, tolerance profile, and weight management trajectory to guide the transition decision.
How Wegovy Works for Prescription Weight Loss Success
Understanding Wegovy's mechanism helps clarify why some patients may consider changing from Wegovy to Mounjaro for enhanced results. Wegovy works as a GLP-1 receptor agonist, mimicking the natural hormone GLP-1 that signals fullness to the brain after meals. This action reduces appetite, promotes earlier satiety with smaller portions, and may help reduce food cravings by acting on appetite centres in the brain. The once-weekly injection via the FlexTouch pen provides consistent therapeutic levels throughout the week. The structured dose escalation from 0.25mg to 2.4mg allows gradual tolerance development whilst maximising therapeutic benefit. This mechanism makes Wegovy particularly effective for patients whose weight management challenges stem from appetite control and portion size management.
Starting Your Wegovy Treatment Through EverydayMeds
The process of obtaining Wegovy, or transitioning from another treatment, begins with our comprehensive 3-minute online clinical assessment. This evaluation covers your medical history, current medications, weight management goals, and suitability for GLP-1 receptor agonist therapy. Following submission, our qualified prescribers review your assessment within standard 3 working days, or 24 hours with our express service. Once approved, your Wegovy is dispatched via next-day delivery using cold-chain temperature-controlled packaging to maintain medication integrity. Our GPhC-registered pharmacy (#9012878) ensures all prescriptions meet UK regulatory standards and MHRA requirements. Ongoing support includes treatment monitoring, side effect management, and guidance on dose escalation timing.
Storage and Practical Considerations for Wegovy Treatment
Practical storage differences may influence whether you can change from Wegovy to Mounjaro for lifestyle compatibility. Wegovy requires refrigeration at 2-8°C before first use but offers superior travel convenience with 6 weeks room temperature stability below 30°C once removed from the fridge. This storage advantage over Mounjaro's 21-day room temperature limit makes Wegovy particularly suitable for frequent travellers or those with irregular schedules. The FlexTouch pen design provides intuitive injection with clear dose display and audible click confirmation. Each pen contains four weekly doses, with patients progressing through the escalation schedule: weeks 1-4 at 0.25mg, weeks 5-8 at 0.5mg, continuing until reaching the 2.4mg maintenance dose. Injection site rotation between thigh, abdomen, or upper arm helps maintain comfort and absorption consistency.
Comparing Treatment Transition Options for Weight Management
When evaluating whether you can change from Wegovy to Mounjaro, consider the unique dual-receptor mechanism that Mounjaro offers through its tirzepatide formulation. Unlike Wegovy's single GLP-1 pathway, Mounjaro targets both GIP and GLP-1 receptors, potentially offering different therapeutic benefits for certain patients. However, this doesn't necessarily mean superior results, as individual responses vary significantly between patients.
The transition timing and methodology require careful clinical supervision, as switching between GLP-1 treatments involves considerations around washout periods, dose equivalencies, and side effect monitoring. Some patients may benefit from changing treatments due to tolerance issues, plateau effects, or preferential response patterns. Both Wegovy and Mounjaro are available from EverydayMeds, allowing our prescribers to help determine which treatment aligns best with your weight management objectives and lifestyle requirements.
Securing Your Prescription Weight Loss Treatment Today
Whether you're starting Wegovy or considering changing from Wegovy to Mounjaro, EverydayMeds provides comprehensive support for your weight management journey. Our new customers receive £40 off their first order with code FIRST40, whilst returning customers save with code DOSE25, both applied at checkout. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment and explore our bundle options designed for treatment continuity. Our expert clinical team stands ready to guide your prescription weight loss decisions with evidence-based recommendations tailored to your individual circumstances. Remember that sustainable weight management requires commitment to both medication adherence and lifestyle modifications for optimal results.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
